FDA Approves Allergan Aesthetics’ Juvéderm Volux XC for Jawlines

The FDA has approved Allergan Aesthetics’ Juvéderm Volux XC for improvement in jawline definition in adults 21 years and older who have moderate-to-severe loss of definition.

Juvéderm products use a modified hyaluronic acid, or HA, a natural substance in the body that delivers volume to the skin. The treatment helps add volume to the face without surgery.

The HA products were previously cleared for improving other facial features including cheeks, chin, lines and lips.

The approval was supported by a study in which the treatment improved jawline definition at six months in 69.9 percent of participants. Almost three quarters of participants were satisfied with the improvement in their appearance, the company said.

Allergan Aesthetics plans to launch a training program for healthcare providers on how to use the product in the fall and to release the product more widely in early 2023.